Redhill Biopharma (NASDAQ:RDHL – Get Free Report) and Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Redhill Biopharma and Indaptus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Redhill Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Indaptus Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Indaptus Therapeutics has a consensus target price of $140.00, suggesting a potential upside of 3,843.66%. Given Indaptus Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Indaptus Therapeutics is more favorable than Redhill Biopharma.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Redhill Biopharma | $8.04 million | 0.65 | -$8.27 million | $486.75 | 0.00 |
| Indaptus Therapeutics | N/A | N/A | -$15.02 million | ($37.66) | -0.09 |
Redhill Biopharma has higher revenue and earnings than Indaptus Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Redhill Biopharma has a beta of 4.57, indicating that its share price is 357% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.
Profitability
This table compares Redhill Biopharma and Indaptus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Redhill Biopharma | N/A | N/A | N/A |
| Indaptus Therapeutics | N/A | -612.59% | -243.78% |
Insider and Institutional Ownership
7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 20.8% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Redhill Biopharma beats Indaptus Therapeutics on 8 of the 12 factors compared between the two stocks.
About Redhill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
